Browse > Article
http://dx.doi.org/10.3345/kjp.2010.53.2.228

The characteristic laboratory findings of non-responsiveness to intravenous immunoglobulin in children with Kawasaki disease  

Cho, Han Gil (Department of Pediatrics, Chonnam National University Medical School Chonnam National University Hospital)
Cho, Young Kuk (Department of Pediatrics, Chonnam National University Medical School Chonnam National University Hospital)
Ma, Jae Sook (Department of Pediatrics, Chonnam National University Medical School Chonnam National University Hospital)
Publication Information
Clinical and Experimental Pediatrics / v.53, no.2, 2010 , pp. 228-234 More about this Journal
Abstract
Purpose : Although intravenous immunoglobulin (IVIG) treatment is an effective first-line treatment for Kawasaki disease, 10-20% of the patients develop persistent fever or coronary artery complications. Medical records of Kawasaki disease patients were reviewed to assess the characteristic laboratory findings of IVIG nonresponsiveness. Methods : We reviewed the clinical records of 118 children with Kawasaki disease who were treated at the Chonnam National University Hospital from March 2003 to February 2008. The laboratory findings of the IVIG-responder group (n=110) and the IVIG-nonresponder group (n=8) were compared at admission day and at 48 hours and 14 days after IVIG administration. Results : At admission, the level of creatine kinase (CK) was lower (P =0.03) and that of total protein was higher (P <0.01) in the nonresponders than in the responders. At 48 hours after IVIG administration, the white blood cell (WBC) count (P =0.04) and neutrophil% (P <0.01) was higher in the nonresponders than in the responders. The neutrophil% (P <0.01) and CK (P =0.01) level at admission was lower than that at 48 hours after IVIG administration in the responders; this decrease was not as apparent in the nonresponders. Conclusion : IVIG nonresponders have lower CK and higher total protein levels at admission and higher WBC count and neutrophil% at 48 hours after IVIG administration. The decrease in the neutrophil% and CK level between at admission and at 48 hours after IVIG administration is remarkably higher in responders than in nonresponders.
Keywords
Kawasaki disease; Intravenous immunoglobulin; Treatment failures;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Kil HR. Recent advances in clinical field of Kawasaki disease. J Korean Pediatr Cardiol 2002;6:75-80
2 Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi 1967;16:178-222   PUBMED
3 Fujiwara H, Hamashima Y. Pathology of the heart in Kawasaki disease. Pediatrics 1978;61:100-7   PUBMED   ScienceOn
4 Engle MA, Fatica NS, Bussel JB, O'Loughlin JE, Snyder MS, Lesser ML. Clinical trial of single-dose intravenous gamma globulin in acute Kawasaki disease. Preliminary reort. Am J Dis Child 1989;143:1300-4   PUBMED   ScienceOn
5 Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, et. al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984;2:1055-8   PUBMED
6 Joffe A, Kabani A, Jadavji T. Atypical and complicated Kawasaki disease in infants. Do we need criteria? West J Med 1995;162:322-7   PUBMED   ScienceOn
7 Yun SW. Diagnostic value of serum cardiac Troponin T, Troponin I and CK-MB in acute Kawasaki disease. Korean Circ J 2009;34:582-92
8 Wright DA, Newburger JW, Baker A, Sundel RP. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996;128:146-9   DOI   ScienceOn
9 Kim NY, Chang CH, Lee DS, Kim DK, Choi SM, Kim WT. A clinical study of intravenous gammaglobulin retreatment in Kawasaki disease. J Korean Pediatr Soc 2000;43:223-8
10 Hong DE, Lee KY, Han JW, Hwang SS, Lee KS. Treatment of intravenous immune-globulin resistant Kawasaki disease with corticosteroids. J Korean Pediatr Soc 1997;40:1453-7
11 Muta H, Ishii M, Furui J, Nakamura Y, Matsuishi T. Risk factors associated with the need for additional intravenous gamma-globulin therapy for Kawasaki disease. Acta Paediatr 2006;95:189-93   DOI   ScienceOn
12 Burns JC, Glode MP. Kawasaki syndrome. Lancet 2004;364:533-44   DOI   ScienceOn
13 Ogino H, Ogawa M, Harima Y, Kono S, Ohkuni H, Nishida M, et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Prog Clin Biol Res 1987;250:555-6   PUBMED
14 De Zorzi A, Colan SD, Gauvreau K, Baker AL, Sundel RP, Newburger JW. Coronary artery dimensions may be misclassified as normal in Kawasaki disease. J Pediatr 1998;133:254-8   DOI   ScienceOn
15 Shim SY, Heo MY, Kim HS, Sonh S. High-dose intravenous immmune globulin retreatment in Kawasaki disease. J Korean Pediatr Soc 2002;45:1273-7
16 Cho EY, Lee MH, Kang KS, No ES, Lee DJ, Choi MB, et al. Serum C-Reactive Protein as a predictor for cardiac sequelae in Kawasaki disease. J Korean Pediatr Cardiol 2002;6:90-5
17 Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 2000;105:e78   DOI   PUBMED   ScienceOn
18 Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease. J Pediatr 2000;137:177-80   DOI   ScienceOn
19 Newburger JW, Burns JC. Kawasaki syndrome. Cardiol Clin 1989;7:453-65   PUBMED   ScienceOn
20 Inoue Y, Kobavashi T, Tomomasa T, Morikawa A. Macro creatine kinase in Kawasaki disease. Pediatr Cardiol 1999;20:206-7   DOI   ScienceOn
21 Leem BY, Chung CS, Cha SH, Choi YM, Ahn CI. A comparative study of therapeutic effect of intravenous gammaglobulin plus aspirin versus aspirin alone in Kawasaki syndrome. J Korean Pediatr Soc 1989;32:1408-14
22 Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, et al. Treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986;315:341-7   DOI   PUBMED   ScienceOn
23 Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C. Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol 2003;24:145-8   DOI   ScienceOn
24 Fukunishi M, Kikkawa M, Hamana K, Onodera T, Matsuzaki K, Matumoto Y, et al. Prediction of non-response to intravenous high-dose gammaglobulin therapy in patients with Kawasaki disease at onset. J Pediatr 2000;137:172-6   DOI   ScienceOn
25 Ahn SY, Hong SY, Kim NS, Lee HB, Moon SJ, Lee H. Comparison between treatment with aspirin alone and the combined treatment with aspirin with gammaglobulin in Kawasaki disease. J Korean Pediatr Soc 1990;33:1380-7